gary phillips
- Home
- gary phillips
Fibrosis is the simple disease process that’s more important than you think
How does a company with a lead asset cancer drug also get into dermatology? What does blood cancer and keloid scars have in common? The answer is: fibrosis. Fibrosis is another word for scarring. It is the key in the process of healing where connective tissue replaces normal tissue to form scar tissue. It’s how
Read MorePublic
Shareholders back Pharmaxis liver cancer treatment trials via oversubscribed capital raise
When the University of Rochester came knocking on the door of biopharmaceutical company Pharmaxis (ASX: PXS), it was a boost from a respected group of researchers for their lead drug candidate PXS-5505 which has continued to draw attention from around the world. By agreement with Pharmaxis, the University of Rochester embarked on preclinical work on
Read MorePublic
This small biotech is the definition of a quiet achiever, here’s why it might be time to tune in
Clinical stage pharmaceutical company Pharmaxis (ASX: PXS) is in a transformation phase as their clinical pipeline progresses towards multiple value inflection points. With two products already on market, the Company has a great base from which to fund their ongoing clinical product development. Adding to that, the company has just completed a capital raise viaRead MorePublic
Global biotech funds commit $7.2m to breakthrough liver and bone cancer trials
Breakthrough clinical trials into new treatments for bone marrow and liver cancer will soon commence after experienced institutional biotech investors with positive track records in companies such as Viralytics, Ophthea and Avita committed $7.2 million towards funding the trials for Pharmaxis (ASX: PXS) and their hero drug PXS-5505. Unlike other cancer treatment drugs on the
Read MorePublic
Cancer drug development company gathering momentum as more researchers worldwide take notice
With promising data starting to flow from clinical trials, more and more medical researchers are tuning in to the Pharmaxis (ASX: PXS) story. The drug development Company has a diverse pipeline backed by solid science with drugs engineered by their world renowned drug development team. Lead drug candidate PXS-5505 is designed to treat myelofibrosis, aRead MorePublic
Small Caps Watch: Pharmaxis CEO Gary Phillips
Sitting down with Gary Phillips reminds me of chatting to my favourite chemistry teacher in high school. Not that you’d usually compare a biotech company CEO to a past teacher but much like Mr McLeod, Gary has the unique ability to get you excited about science. Gary heads up Pharmaxis (ASX: PXS), a Sydney-based biotechnologyRead MorePublic
- 1
- 2